Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1981 2
1986 1
1989 3
1990 2
1992 1
1995 1
1996 1
1997 1
1998 2
2003 1
2006 1
2007 1
2012 1
2013 2
2015 2
2017 2
2018 1
2019 3
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Goggins M, et al. Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31. Gut. 2020. PMID: 31672839 Free PMC article.
BACKGROUND AND AIM: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation statu …
BACKGROUND AND AIM: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommen …
Capecitabine for the treatment of pancreatic cancer.
Siddiqui NS, Godara A, Byrne MM, Saif MW. Siddiqui NS, et al. Expert Opin Pharmacother. 2019 Mar;20(4):399-409. doi: 10.1080/14656566.2018.1560422. Epub 2019 Jan 16. Expert Opin Pharmacother. 2019. PMID: 30649964 Review.
Today, capecitabine is extensively used for the treatment of many solid malignancies, with a particular focus in breast and gastrointestinal tumors, but also in pancreatic cancer. Areas covered: This review summarizes the pharmacology and the clinical evidence relevant to …
Today, capecitabine is extensively used for the treatment of many solid malignancies, with a particular focus in breast and gastrointestinal …
Neoadjuvant treatment in localized and resectable cancer of the pancreas: a new therapeutic paradigm.
Martí-Cruchaga P, Cienfuegos JA, Rotellar F. Martí-Cruchaga P, et al. Rev Esp Enferm Dig. 2022 Jul;114(7):371-374. doi: 10.17235/reed.2022.8925/2022. Rev Esp Enferm Dig. 2022. PMID: 35638765
Ductal carcinoma of the pancreas (DCP) is one of the most devastating tumors and ranks fourth among the causes of death from cancer. It is estimated that by 2030 it will be among the top three "cancer killers", along with lung cancer and hepatocarcinom …
Ductal carcinoma of the pancreas (DCP) is one of the most devastating tumors and ranks fourth among the causes of death from cance …
Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies.
Bardou M, Le Ray I. Bardou M, et al. Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):881-92. doi: 10.1016/j.bpg.2013.09.006. Epub 2013 Oct 1. Best Pract Res Clin Gastroenterol. 2013. PMID: 24182608 Review.
Cancer of the pancreas is the second most frequent digestive cancer in the US, accounting for about 44,000 new cases per year. ...Radical surgery offers the only curative treatment of pancreatic cancer. Alternative or combined therapeutic option …
Cancer of the pancreas is the second most frequent digestive cancer in the US, accounting for about 44,000 new cases pe …
Chemotherapy in the treatment of cancer of the pancreas.
Glimelius B. Glimelius B. J Hepatobiliary Pancreat Surg. 1998;5(3):235-41. doi: 10.1007/s005340050040. J Hepatobiliary Pancreat Surg. 1998. PMID: 9880769 Review.
No standard regimen is defined, although one drug, gemcitabine, has been approved in some countries for the treatment of advanced pancreatic cancer. The two randomized adjuvant trials included a very small number of patients, and, although a survival benefit was seen, conc …
No standard regimen is defined, although one drug, gemcitabine, has been approved in some countries for the treatment of advanced pancreatic …
The clinical utility of the CA 19-9 tumor-associated antigen.
Steinberg W. Steinberg W. Am J Gastroenterol. 1990 Apr;85(4):350-5. Am J Gastroenterol. 1990. PMID: 2183589 Review.
Since Koprowski and coworkers discovered the CA 19-9 antigen 10 yr ago, it has become the most useful blood test in the diagnosis and management of patients with cancer of the pancreas. With an upper limit of normal of 37 U/ml, the assay's overall sensitivity is app …
Since Koprowski and coworkers discovered the CA 19-9 antigen 10 yr ago, it has become the most useful blood test in the diagnosis and manage …
The role of positron emission tomography in the management of pancreatic cancer.
Pakzad F, Groves AM, Ell PJ. Pakzad F, et al. Semin Nucl Med. 2006 Jul;36(3):248-56. doi: 10.1053/j.semnuclmed.2006.03.005. Semin Nucl Med. 2006. PMID: 16762614 Review.
The role of positron emission tomography (PET) and PET/computed tomography (CT) in the assessment of a patient presenting with cancer of the pancreas is discussed in the overall context of the management of this condition. The clinical limitations persist, with many …
The role of positron emission tomography (PET) and PET/computed tomography (CT) in the assessment of a patient presenting with cancer …
Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements.
Dbouk M, Brewer Gutierrez OI, Lennon AM, Chuidian M, Shin EJ, Kamel IR, Fishman EK, He J, Burkhart RA, Wolfgang CL, Hruban RH, Goggins MG, Canto MI. Dbouk M, et al. Pancreatology. 2021 Apr;21(3):613-621. doi: 10.1016/j.pan.2021.01.017. Epub 2021 Feb 2. Pancreatology. 2021. PMID: 33593706
BACKGROUND: Objectives: Pancreatic cysts are frequently detected in high-risk individuals (HRI) undergoing surveillance for pancreatic cancer. The International Cancer of the Pancreas Screening (CAPS) Consortium developed consensus recommendations for surgica …
BACKGROUND: Objectives: Pancreatic cysts are frequently detected in high-risk individuals (HRI) undergoing surveillance for pancreatic ca …
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium. Canto MI, et al. Gut. 2013 Mar;62(3):339-47. doi: 10.1136/gutjnl-2012-303108. Epub 2012 Nov 7. Gut. 2013. PMID: 23135763 Free PMC article.
BACKGROUND: Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. ...It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC …
BACKGROUND: Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplas …
30 results